PH12018501274A1 - Stabilized pharmaceutical composition containing pemetrexed or pharmaceutically acceptable salt thereof - Google Patents
Stabilized pharmaceutical composition containing pemetrexed or pharmaceutically acceptable salt thereofInfo
- Publication number
- PH12018501274A1 PH12018501274A1 PH12018501274A PH12018501274A PH12018501274A1 PH 12018501274 A1 PH12018501274 A1 PH 12018501274A1 PH 12018501274 A PH12018501274 A PH 12018501274A PH 12018501274 A PH12018501274 A PH 12018501274A PH 12018501274 A1 PH12018501274 A1 PH 12018501274A1
- Authority
- PH
- Philippines
- Prior art keywords
- pemetrexed
- stability
- pharmaceutical composition
- present
- pharmaceutically acceptable
- Prior art date
Links
- QOFFJEBXNKRSPX-ZDUSSCGKSA-N pemetrexed Chemical compound C1=N[C]2NC(N)=NC(=O)C2=C1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QOFFJEBXNKRSPX-ZDUSSCGKSA-N 0.000 title abstract 5
- 229960005079 pemetrexed Drugs 0.000 title abstract 5
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 150000003839 salts Chemical class 0.000 title abstract 2
- 238000002360 preparation method Methods 0.000 abstract 2
- 238000011109 contamination Methods 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000004108 freeze drying Methods 0.000 abstract 1
- 239000007788 liquid Substances 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 230000000813 microbial effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020150178339A KR101693675B1 (ko) | 2015-12-14 | 2015-12-14 | 페메트렉시드 또는 그의 약제학적으로 허용가능한 염을 함유하는 안정화된 약학조성물 |
| PCT/KR2016/014594 WO2017105059A1 (ko) | 2015-12-14 | 2016-12-13 | 페메트렉시드 또는 그의 약제학적으로 허용가능한 염을 함유하는 안정화된 약학조성물 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PH12018501274A1 true PH12018501274A1 (en) | 2019-02-04 |
Family
ID=57832487
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH12018501274A PH12018501274A1 (en) | 2015-12-14 | 2018-06-14 | Stabilized pharmaceutical composition containing pemetrexed or pharmaceutically acceptable salt thereof |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US10792285B2 (https=) |
| EP (1) | EP3391908A4 (https=) |
| JP (3) | JP2019502751A (https=) |
| KR (1) | KR101693675B1 (https=) |
| CN (1) | CN108463251A (https=) |
| HK (1) | HK1255313A1 (https=) |
| MY (1) | MY191043A (https=) |
| PH (1) | PH12018501274A1 (https=) |
| WO (1) | WO2017105059A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202000204A (zh) * | 2018-06-20 | 2020-01-01 | 日商日本化藥股份有限公司 | 培美曲塞鈉注射用溶液製劑及其製造方法 |
| CN116474219A (zh) * | 2019-06-28 | 2023-07-25 | 四川普锐特药业有限公司 | 保持给药均一度的药物流体分配器及右美托咪定鼻喷器 |
| CN117693334B (zh) * | 2022-06-09 | 2025-11-18 | 上海云晟研新生物科技有限公司 | 培美曲塞二钠液体组合物、其制备方法及应用 |
| JP2024006619A (ja) | 2022-07-04 | 2024-01-17 | セイコーエプソン株式会社 | 印刷装置、情報処理装置、情報処理システム、処理方法、及び、プログラム |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR0162654B1 (ko) | 1989-12-11 | 1998-11-16 | 알렌 제이. 시니스갤리 | N-(피롤로[2,3-d]피리미딘-3-일아크릴)-글루타민산 유도체 |
| US6686365B2 (en) | 2000-02-04 | 2004-02-03 | Eli Lilly And Company | Pharmaceutical composition |
| WO2001056575A1 (en) * | 2000-02-04 | 2001-08-09 | Eli Lilly And Company | Pharmaceutical composition comprising pemetrexed together with monothioglycerol l-cystein or thioglycolic acid |
| WO2012015810A2 (en) * | 2010-07-28 | 2012-02-02 | Eagle Pharmaceuticals, Inc. | Pharmaceutical compositions containing pemetrexed having extended storage stability |
| KR20130122065A (ko) | 2012-04-30 | 2013-11-07 | 씨제이제일제당 (주) | 페메트렉시드를 함유하는 안정화된 주사용 액상 제제 |
| EP2666463A1 (en) * | 2012-05-21 | 2013-11-27 | Synthon BV | Stabilized liquid composition comprising pemetrexed |
| EP2854768B2 (en) * | 2012-05-30 | 2025-06-18 | Fresenius Kabi Oncology Limited | Pharmaceutical compositions of pemetrexed |
| DE102012010774A1 (de) * | 2012-05-31 | 2013-12-05 | Stada Arzneimittel Ag | Pharmazeutische Pemetrexed-Lösung |
| KR101260636B1 (ko) | 2012-11-29 | 2013-05-13 | 씨제이제일제당 (주) | 안정화된 페메트렉시드 제제 |
| KR101485243B1 (ko) | 2013-05-08 | 2015-01-21 | 씨제이헬스케어 주식회사 | 안정화된 페메트렉시드 제제 |
| JP6094388B2 (ja) * | 2013-06-07 | 2017-03-15 | ニプロ株式会社 | ペメトレキセドを含む注射用組成物 |
| EP3040074B1 (en) * | 2013-10-03 | 2018-07-25 | Fujifilm Corporation | Injection preparation and method for producing same |
| JP6099557B2 (ja) * | 2013-12-27 | 2017-03-22 | 富士フイルム株式会社 | 注射液製剤及びその製造方法 |
| KR101574875B1 (ko) * | 2014-02-13 | 2015-12-04 | 건양대학교산학협력단 | 안정화된 페니실린 복합 현탁 제제 |
| ES2686870T3 (es) * | 2014-03-28 | 2018-10-22 | Fujifilm Corporation | Preparación de inyección y método para producirla |
| WO2016151365A1 (en) * | 2015-03-26 | 2016-09-29 | Ftf Pharma Private Limited | Pharmaceutical composition of pemetrexed |
| KR101919436B1 (ko) * | 2015-05-28 | 2018-11-16 | 주식회사 삼양바이오팜 | 안정화된 약학 조성물 및 그의 제조방법 |
-
2015
- 2015-12-14 KR KR1020150178339A patent/KR101693675B1/ko active Active
-
2016
- 2016-12-13 CN CN201680073091.9A patent/CN108463251A/zh active Pending
- 2016-12-13 HK HK18114448.9A patent/HK1255313A1/zh unknown
- 2016-12-13 JP JP2018550317A patent/JP2019502751A/ja active Pending
- 2016-12-13 EP EP16876001.5A patent/EP3391908A4/en not_active Withdrawn
- 2016-12-13 US US16/061,450 patent/US10792285B2/en not_active Expired - Fee Related
- 2016-12-13 MY MYPI2018702294A patent/MY191043A/en unknown
- 2016-12-13 WO PCT/KR2016/014594 patent/WO2017105059A1/ko not_active Ceased
-
2018
- 2018-06-14 PH PH12018501274A patent/PH12018501274A1/en unknown
-
2020
- 2020-05-27 JP JP2020091920A patent/JP2020125359A/ja active Pending
-
2022
- 2022-05-31 JP JP2022088229A patent/JP2022107687A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2020125359A (ja) | 2020-08-20 |
| HK1255313A1 (zh) | 2019-08-16 |
| MY191043A (en) | 2022-05-30 |
| EP3391908A1 (en) | 2018-10-24 |
| WO2017105059A1 (ko) | 2017-06-22 |
| US10792285B2 (en) | 2020-10-06 |
| CN108463251A (zh) | 2018-08-28 |
| JP2022107687A (ja) | 2022-07-22 |
| JP2019502751A (ja) | 2019-01-31 |
| US20200261458A1 (en) | 2020-08-20 |
| KR101693675B1 (ko) | 2017-01-06 |
| EP3391908A4 (en) | 2019-08-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202102906B (en) | Liquid protein formulations containing viscosity-lowering agents | |
| PH12018501274A1 (en) | Stabilized pharmaceutical composition containing pemetrexed or pharmaceutically acceptable salt thereof | |
| HRP20220692T1 (hr) | Brzodjelujući pripravci inzulina | |
| CL2014001437A1 (es) | Compuestos derivados de aril dihidropiridinona y piperidinona como inhibidores de monoacilglicerol aciltransferasa (mgat2); composicion y combinacion farmaceutica; y uso en el tratamiento y prevencion de diabetes, hiperglucemia, retinopatia, sindrome metabolico, entre otras enfermedades. | |
| UA117103C2 (uk) | Сполука, яка має активність агоніста глюкагону | |
| WO2015095624A3 (en) | Drug mixing and delivery system and method | |
| IN2015KN00005A (https=) | ||
| PE20140616A1 (es) | Composicion que comprende aflibercept, acido folinico, 5-fluorouracilo (5-fu) e irinotecan (folfiri) | |
| ZA201707096B (en) | Heteroaryl derivative or pharmaceutically acceptable salt thereof, preparation method therefor, and pharmaceutical composition for preventing or treating diseases associated with pi3 kinases, containing same as active ingredient | |
| MY189913A (en) | Preparation containing tetracyclic compound at high dose | |
| EP4650370A3 (en) | Pharmaceutical composition for prevention and/or treatment of atopic dermatitis containing il-31 antagonist as active ingredient | |
| EA201790726A1 (ru) | Фармацевтическая композиция для лечения язвенного колита | |
| AU2015242791A1 (en) | Drug Delivery Enhancer Comprising Substance For Activating Lysophospholipid Receptors | |
| WO2016100949A3 (en) | Method and compositions for dissolving or solubilizing therapeutic agents | |
| PH12017502252A1 (en) | Stable pharmaceutical composition for oral administration | |
| PH12017501828B1 (en) | Stabilized pharmaceutical composition and method for preparing same | |
| MD20180049A2 (ro) | Compoziţie farmaceutică | |
| MD20170071A2 (ro) | Compoziţii injectabile de paracetamol | |
| SG194458A1 (en) | Solid pharmaceutical composition | |
| NZ705340A (en) | Amine salt and crystals thereof | |
| MY192061A (en) | Pharmaceutical composition for external use | |
| EA201800360A1 (ru) | Способ получения фармацевтической композиции, содержащей бендамустин, фармацевтическая композиция бендамустина | |
| HK1226310A1 (en) | Liquid protein formulations containing water soluble organic dyes | |
| EA201891136A1 (ru) | Фармацевтическая композиция, содержащая в качестве активного ингредиента производное 7-азаиндолин-2-она или его фармацевтически приемлемую соль | |
| PL2852400T3 (pl) | Analog insuliny lub jego farmaceutycznie dopuszczalna sól, kompozycja farmaceutyczna o przedłużonym działaniu terapeutycznym, zastosowanie analogu insuliny, sposób dawkowania oraz sposób leczenia cukrzycy |